XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Company (IPO / Went public)
5 HaCharoshet St.
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)
|Pyrazole compounds||Feb 15, 2005||Dec 11, 2012||Patent|
|4-thio substituted quinoline and naphthyridine compounds||Aug 22, 2007||Mar 27, 2012||Patent|
|3,4-disubstituted coumarin and quinolone compounds||Mar 29, 2005||Nov 01, 2011||Patent|
|Benzofuran compounds||May 16, 2005||Aug 09, 2011||Patent|
|Compounds and methods for treatment of hcv||Oct 15, 2007||Apr 12, 2011||Patent|